PMC:7784824 / 16958-19217
Annnotations
LitCovid-PubTator
{"project":"LitCovid-PubTator","denotations":[{"id":"271","span":{"begin":562,"end":572},"obj":"Species"},{"id":"363","span":{"begin":322,"end":330},"obj":"Species"},{"id":"364","span":{"begin":422,"end":427},"obj":"Species"},{"id":"365","span":{"begin":428,"end":441},"obj":"Species"},{"id":"367","span":{"begin":908,"end":916},"obj":"Species"},{"id":"368","span":{"begin":959,"end":967},"obj":"Species"},{"id":"369","span":{"begin":1089,"end":1099},"obj":"Species"},{"id":"370","span":{"begin":1632,"end":1640},"obj":"Species"},{"id":"371","span":{"begin":1131,"end":1141},"obj":"Species"},{"id":"372","span":{"begin":313,"end":321},"obj":"Disease"},{"id":"373","span":{"begin":899,"end":907},"obj":"Disease"}],"attributes":[{"id":"A271","pred":"tao:has_database_id","subj":"271","obj":"Tax:2697049"},{"id":"A363","pred":"tao:has_database_id","subj":"363","obj":"Tax:9606"},{"id":"A364","pred":"tao:has_database_id","subj":"364","obj":"Tax:9606"},{"id":"A365","pred":"tao:has_database_id","subj":"365","obj":"Tax:11118"},{"id":"A367","pred":"tao:has_database_id","subj":"367","obj":"Tax:9606"},{"id":"A368","pred":"tao:has_database_id","subj":"368","obj":"Tax:9606"},{"id":"A369","pred":"tao:has_database_id","subj":"369","obj":"Tax:2697049"},{"id":"A370","pred":"tao:has_database_id","subj":"370","obj":"Tax:9606"},{"id":"A371","pred":"tao:has_database_id","subj":"371","obj":"Tax:2697049"},{"id":"A372","pred":"tao:has_database_id","subj":"372","obj":"MESH:C000657245"},{"id":"A373","pred":"tao:has_database_id","subj":"373","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Recently, the first studies evaluating several commercial serology assays have been published. Geurts van Kessel et al [17]. studied three rapid tests, four ELISAs and a high throughput chemiluminescent assay. Sensitivity ranging from 81–100% was calculated by using a total of 187 sera from 107 RT-PCR confirmed COVID-19 patients. Specificity was determined using 147 serum and plasma samples from individuals exposed to human coronaviruses and other respiratory viruses with values ranging from 85–100%. Similar to our findings, the performance of the Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin) was worst with a sensitivity of 81% (compared to 59% in our results) and specificity of 90% (compared with 100% in our results). The group of Haselmann et al [16]. evaluated the performance of two IgG ELISA assays and one IgG electrochemiluminescence immunoassay (ECLIA) based on 51 serum samples from 26 COVID-19 patients and another 51 serum samples from control patients. They report a sensitivity of 92–100% and specificity of 84–96%. The Austrian Red Cross Blood Service [15] evaluated 100 SARS-CoV-2 convalescent plasma donors and SARS-CoV-2 antibodies were characterized using three different IgG-ELISAs (EUROIMMUN IgG and NCP-IgG ELISA, Wantai ELISA), two CLIA (Elecsys, LIAISON) and two lateral flow tests (MEDsan IgM/IgG-Rapid-Test, Wantai Rapid Test). The Wantai ELISA and the Elecsys provided the highest sensitivities in this sample (98 and 95 % respectively). Serrano et al [18]. compared the performance of 3 lateral flow immunoassays (IgM/IgG combined) to 2 ELISAs (IgA and IgG) in serum samples from 109 RT-PCR confirmed patients in different weeks after symptom onset. The IgA ELISA was most sensitive the first week after symptom onset (71%). The sensitivity improved to 97% for IgA ELISA in the second week. In the third week IgA ELISA, IgG ELISA and 2 out 3 IgG lateral flow tests had a sensitivity of \u003e 96%. The lateral flow immunoassays showed variable performances. Pieri et al. also found that IgA detected by the ELISA assay might be a more reliable and stable early serological marker than IgM. Instead, IgG, as expected, showed stable level after 10 days from symptoms onset [21]. These findings are in accordance with our study results."}
LitCovid-sentences
{"project":"LitCovid-sentences","denotations":[{"id":"T184","span":{"begin":0,"end":94},"obj":"Sentence"},{"id":"T185","span":{"begin":95,"end":209},"obj":"Sentence"},{"id":"T186","span":{"begin":210,"end":331},"obj":"Sentence"},{"id":"T187","span":{"begin":332,"end":505},"obj":"Sentence"},{"id":"T188","span":{"begin":506,"end":722},"obj":"Sentence"},{"id":"T189","span":{"begin":723,"end":968},"obj":"Sentence"},{"id":"T190","span":{"begin":969,"end":1032},"obj":"Sentence"},{"id":"T191","span":{"begin":1033,"end":1356},"obj":"Sentence"},{"id":"T192","span":{"begin":1357,"end":1467},"obj":"Sentence"},{"id":"T193","span":{"begin":1468,"end":1680},"obj":"Sentence"},{"id":"T194","span":{"begin":1681,"end":1755},"obj":"Sentence"},{"id":"T195","span":{"begin":1756,"end":1821},"obj":"Sentence"},{"id":"T196","span":{"begin":1822,"end":1923},"obj":"Sentence"},{"id":"T197","span":{"begin":1924,"end":1983},"obj":"Sentence"},{"id":"T198","span":{"begin":1984,"end":2115},"obj":"Sentence"},{"id":"T199","span":{"begin":2116,"end":2202},"obj":"Sentence"},{"id":"T200","span":{"begin":2203,"end":2259},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Recently, the first studies evaluating several commercial serology assays have been published. Geurts van Kessel et al [17]. studied three rapid tests, four ELISAs and a high throughput chemiluminescent assay. Sensitivity ranging from 81–100% was calculated by using a total of 187 sera from 107 RT-PCR confirmed COVID-19 patients. Specificity was determined using 147 serum and plasma samples from individuals exposed to human coronaviruses and other respiratory viruses with values ranging from 85–100%. Similar to our findings, the performance of the Liaison SARS-CoV-2 S1/S2 IgG (DiaSorin) was worst with a sensitivity of 81% (compared to 59% in our results) and specificity of 90% (compared with 100% in our results). The group of Haselmann et al [16]. evaluated the performance of two IgG ELISA assays and one IgG electrochemiluminescence immunoassay (ECLIA) based on 51 serum samples from 26 COVID-19 patients and another 51 serum samples from control patients. They report a sensitivity of 92–100% and specificity of 84–96%. The Austrian Red Cross Blood Service [15] evaluated 100 SARS-CoV-2 convalescent plasma donors and SARS-CoV-2 antibodies were characterized using three different IgG-ELISAs (EUROIMMUN IgG and NCP-IgG ELISA, Wantai ELISA), two CLIA (Elecsys, LIAISON) and two lateral flow tests (MEDsan IgM/IgG-Rapid-Test, Wantai Rapid Test). The Wantai ELISA and the Elecsys provided the highest sensitivities in this sample (98 and 95 % respectively). Serrano et al [18]. compared the performance of 3 lateral flow immunoassays (IgM/IgG combined) to 2 ELISAs (IgA and IgG) in serum samples from 109 RT-PCR confirmed patients in different weeks after symptom onset. The IgA ELISA was most sensitive the first week after symptom onset (71%). The sensitivity improved to 97% for IgA ELISA in the second week. In the third week IgA ELISA, IgG ELISA and 2 out 3 IgG lateral flow tests had a sensitivity of \u003e 96%. The lateral flow immunoassays showed variable performances. Pieri et al. also found that IgA detected by the ELISA assay might be a more reliable and stable early serological marker than IgM. Instead, IgG, as expected, showed stable level after 10 days from symptoms onset [21]. These findings are in accordance with our study results."}